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INTRODUCTION
Mitral valve (MV) surgery accounts for one-third of all heart valve surgeries in the USA [1] . Primary valve repair has emerged as the preferred strategy for MV surgery especially in patients with myxomatous or degenerative MV disease [2] . MV repair compared with replacement is associated with improved early and long-term survival [2, 3] . In contrast to the developed countries where degenerative disease is the most common indication for MV surgery, rheumatic heart disease (RHD) is the predominant cause of MV surgery in the developing world [4, 5] . Contrary to non-rheumatic disease, rheumatic MVs are technically less amenable to repair due to significant fibrosis, scarring and sub-valvular pathology [6, 7] . Furthermore, concomitant aortic valve (AV) involvement is frequent in patients with rheumatic MV disease, varying between 20 and 50%. As a result, a significant proportion of these patients need dual valve surgery [8, 9] . While improvements in repair technique and surgical expertise have led to increased adoption of repair as the initial strategy in these patients, the results of MV repair in degenerative valvular disease cannot be extrapolated to the rheumatic population, particularly in the setting of concomitant AV replacement [10, 11] . The comparative outcomes of MV repair vs replacement in patients undergoing dual valve surgery in predominantly RHD patients have not been studied in any prospective study and conflicting results have been reported by retrospective studies. Therefore, in this paper, we systematically reviewed published literature and performed a meta-analysis comparing outcomes of MV repair vs MV replacement in patients undergoing concomitant AV replacement with particular emphasis on rheumatic patients.
MATERIALS AND METHODS
PubMed, Web of Science and Cochrane databases were searched for studies comparing outcomes of MV repair vs replacement with concomitant aortic valve replacement (AVR) up to 25 January 2014. The search was performed by variously combining the following key terms: MV disease, MV repair, MV replacement, AVR. The results of the search were screened for relevant studies by two of the authors (A.S. and V.A.). Bibliographies of relevant articles and review articles were hand searched for additional studies that were not identified by the primary search. The study inclusion criteria were: (i) direct comparison between MV repair and MV replacement in the setting of concomitant AV replacement; (ii) studies should have reported at least one of the following outcome measures: early mortality, late mortality, thromboembolism (TE), MV reoperation rate or major bleeding complications; (3) the number of patients in each group and the number of outcome events in each group should be available from the manuscript or through correspondence with the authors. Outcome measures were predefined as follows: (i) Early mortality: death from any cause (cardiac and non-cardiac) occurring up to 30 days after surgery (included operative and in-hospital mortality). (ii) Late mortality: death from any cause (cardiac and noncardiac) occurring beyond 30 days and during the follow-up period. The denominator for late mortality was calculated by subtracting the early deaths from the number of patients in that group at the beginning of the study. (iii) MV reoperation rate: any repeat surgery involving the MV after the initial surgery. We did not include AV reoperation as an end point. (iv) TE: any stroke (excluding intracranial bleed), transient ischaemic attack (TIA), peripheral embolism or valve thrombosis (either MV or AV). Some of the studies separately described valve thrombosis which we included under TE to maintain uniformity among studies. (v) Major bleeding: included any bleed that was life threatening or had resulted in death, intracranial bleed regardless of size and location, hospitalization or needed blood transfusion. The denominator for early mortality, MV reoperation, TE and major bleeding was the number of patients for that particular group at the beginning of the study. We excluded studies by the following criteria: (i) published in non-English language journals; (ii) abstract presentations without full text publication; (iii) multivalve surgery involving tricuspid valve (TV) replacement (TV repair was not an exclusion); (iv) studies with < 25 patients in the repair group to minimize bias due to poor operator experience with repair techniques. When there were multiple studies from the same author or institution, only the largest study was included. Data from selected studies were extracted on standardized forms in duplicate by two authors (A.S. and V.A.). This included study size, year of publication, first author, number of patients in each group and outcome events, aetiology of valve disease and baseline demographics. Disagreements were sorted by consensus or by seeking the opinion of the third author (M.K.). The quality of studies was assessed using the Newcastle-Ottawa scoring system for Observational studies [12] . Using the pooled data, meta-analysis was performed following the meta-analysis of observational studies in epidemiology (MOOSE) recommendations [13] . Analyses were conducted based on the intention to treat principle. We could not account for possible censored observations that might have resulted from incomplete follow-up in individual studies due to the lack of all relevant information. We used DerSimonian and Laird weighting and a random effects model to calculate summary estimates and 95% confidence intervals (CIs) for each of the outcome events. Publication bias was assessed visually with a funnel plot and tested statistically using Begg's test and Egger's regression coefficient. Heterogeneity was assessed using Cochran's Q-test and quantified with the I 2 statistic. We performed a sensitivity analysis and assessed the influence of excluding individual studies on the summary effect estimate. Finally, a predefined analysis of studies that had exclusively rheumatic patients was performed. All analyses were done with 
RESULTS
A total of 1202 citations were reviewed of which 20 articles were selected for full text review. Of these, 8 studies with 3924 patients fulfilling all the inclusion criteria were included in the meta-analysis (Table 1) [14] [15] [16] [17] [18] [19] [20] [21] . The mean age of the patients across various studies ranged between 30 and 60 years. There was no statistically significant difference in the age of patients undergoing MV repair vs replacement (mean difference: −2.67 years; 95% CI: −5.4-0.07, P = 0.06). Males accounted for 54% of the population in the MV repair group and 51% in the MV replacement group [14] [15] [16] [17] [18] [19] . RHD patients accounted for 79% of patients in seven studies (n = 2867) excluding the study by Leavitt et al. [20] . Demographic data and underlying aetiology were not available in the study by Leavitt et al. Three studies had exclusively RHD patients (n = 1106) [16] [17] [18] . The mean follow-up varied between 5 years and 16 years [14] [15] [16] [17] [18] [19] . Mixed: rheumatic as well as non-rheumatic aetiology; MV: mitral valve; RHD: rheumatic heart disease.
Early mortality (death from any cause up to 30 days after surgery) was found to be significantly lower with MV repair compared with MV replacement [risk ratio (RR): 0.68, 95% CI: 0.53-0.87, P = 0.003, Fig. 1 ]. Similarly, late mortality was significantly lower in patients undergoing MV repair (RR: 0.76, 95% CI: 0.64-0.90, P = 0.001, Fig. 2 ). The MV reoperation rate was found to be similar in the MV repair and replacement groups (RR: 1.89, 95% CI: 0.87-4.10, P = 0.108, Fig. 3 ). Contrary to expectations, thromboembolism and major bleeding were found to be similar (RR: 0.65, 95% CI: 0.38-1.13, P = 0.128 and RR: 0.88, 95% CI: 0.49-1.57, P = 0.659, respectively). Not surprisingly, anticoagulation practices varied widely among the different studies. In general, for patients who received bioprosthetic valves, warfarin was discontinued 3 months following surgery in the absence of other indications. There was no evidence of publication bias on visual inspection of the funnel plot (Fig. 4) . Egger's test did not demonstrate any statistically significant publication bias or small study effect for the individual outcomes (Table 3) . When studies that exclusively studied RHD patients (three studies [16] [17] [18] ] n = 1106) were analysed separately, we did not find any significant difference in early or late mortality between the MV repair and replacement groups (early mortality RR: 0.92, 95% CI: 0.44-1.9, P = 0.81; late mortality RR: 0.69, 95% CI: 0.39-1.22, P = 0.199). The 
DISCUSSION
In this meta-analysis, we found that, in patients undergoing concomitant aortic and MV surgery, MV repair was associated with lower early and late mortality compared with MV replacement without an increased risk for MV reoperation. It is well-known that MV repair is superior to MV replacement in patients with degenerative MV disease undergoing isolated MV surgery. Accordingly, current guidelines recommend MV repair as the preferred surgical strategy for treating patients with degenerative MV disease. However, with increasing surgical expertise, MV repair is now being employed in patients with more complex MV disease and multivalvular disease. There are no existing recommendations on the best approach for surgical management of patients with multivalve disease, particularly aortic and MV disease. In one of the early studies, Szentpetery et al. [22] demonstrated the feasibility of AV replacement with MV repair in a series of 38 patients, most of whom had degenerative MV disease. Subsequently, a few studies have compared MV repair with replacement in the context of concomitant AV surgery. These studies were retrospective, single-centre series with variable number of patients and yielded diverse results. Thus, the data on the superiority of MV repair in the context of concomitant AV surgery is limited. Our systematic review and meta-analysis suggest that the benefits of MV repair extend to patients undergoing multivalve surgery. This is in agreement with findings from the Society of Thoracic Surgeons registry in which MV repair was associated with a lower operative mortality compared with replacement in the setting of concomitant AV replacement [2] . Our findings extend these observations to late mortality. Two studies (Ho et al. and Kim et al.) reported higher but statistically non-significant early mortality with MV repair compared with replacement (RR: 2.03, P = 0.38 and RR: 2.22, P = 0.29, respectively) [16, 21] . In the study by Ho et al. [16] , heart failure was the predominant cause of early deaths and could have been a result of relatively lower left ventricular ejection fraction in the MV repair group compared with replacement [left ventricle ejection fraction (LVEF): 61.2% ± 8.6 vs 63% ± 7.4, P = 0.007]. Similarly, in the study by Kim et al. [21] the overall LV ejection fraction was lower in the MV repair group (LVEF: 46% ± 13 vs 55% ± 10.3, P < 0.001) and a higher percentage of the patients underwent concomitant coronary artery bypass graft (CABG) (P < 0.001) and aortic root surgery (P = 0.002). This could have accounted for the higher early mortality in the MV repair group in this series. Sensitivity analysis by excluding one study at a time demonstrated that the favourable early mortality results in the MV repair group was largely driven by the study by Leavitt et al. [20] . The reason for this is unclear. We suspect that this may be due to a lower prevalence of RHD in the Leavitt study compared with the other seven studies (79% RHD patients cumulatively). The prevalence of RHD was not available in the series by Levitt et al., but presumably it was infrequent because it mostly included patients who were from the northern New England area since 1987. Furthermore, in an analysis of studies that had exclusively RHD patients, the early mortality benefit of MV repair was no longer seen (RR: 0.92, 95% CI: 0.44-1.90, P = 0.81). Similar to early mortality, late mortality results favoured MV repair over replacement (RR: 0.76, 95% CI: 0.64-0.90, P = 0.001) in our analysis. This was primarily driven by the results of the study by Gillinov et al. [14] , as exclusion of this study abolished this benefit (RR: 0.93, 95% CI: 0.70-1.23, P = 0.609). Notably, RHD accounted for 71% of total patients in this study and late mortality benefit of MV repair was more pronounced in the rheumatic subgroup compared with the non-rheumatic patients, possibly due to a better preserved LV function in the former. However, meta-analysis of studies exclusively involving RHD patients alone did not show any advantage of the MV repair over MV replacement with regard to late mortality (RR: 0.69, 95% CI: 0.39-1.22, P = 0.199). Therefore, the finding of improved early and late survival with MV repair compared with MV replacement in our meta-analysis needs to be interpreted with caution as these results were largely driven by the findings of Leavitt et al. [20] and Gillinov et al. [14] , respectively, and might not apply to patients with RHD undergoing dual valve surgery.
Durability in terms of freedom from subsequent reoperation is an important consideration for any valve repair surgery. The current meta-analysis did not show any significant difference between the two groups in the MV reoperation rate (RR: 1.89, 95% CI: 0.88-4.10, P = 0.108). This was similar to the results of the meta-analysis by Shuhaiber et al. [23] , which also did not show any difference in the reoperation rate between repair vs replacement in the case of isolated MV surgery in patients with predominantly degenerative MV disease. However, when we analysed three studies [16] [17] [18] which had exclusively RHD patients, MV valve repair was associated with a significantly higher reoperation rate (RR: 5.10, P = 0.005). Because of the inherent selection bias (patients with rigid calcified valves, predominantly stenotic MV disease and those with significant involvement of the sub-valvular apparatus are likely to have preferentially received valve replacement), the reoperation rate with the valve repair might actually have been underestimated. In rheumatic patients valve reoperation is probably higher due to significant scarring, involvement of the sub-valvular structures and possibly occult rheumatic activity [24] . Notably, there was significant heterogeneity in the repair techniques employed across various studies. The rate of use of an annuloplasty ring was only 6.3% in the study by Hammamato et al. [15] when compared with over 60% in the study by Ho et al. [16] . These factors could have variably impacted the outcomes of MV repair across the studies.
Thromboembolism, which includes stroke (excluding intracranial bleed), TIA, peripheral embolism and valve thrombosis (mitral and aortic), was found to be similar in both the groups (RR: 0.65, 95% CI: 0.38-1.13, P = 0.128) in this meta-analysis. This was an unexpected finding and exclusion sensitivity analysis revealed that this result was unduly influenced by the study by Hamamoto et al. [15] . Exclusion of this study demonstrated a favourable impact of MV repair on TE (n = 379, RR: 0.51, 95% CI: 0.32-0.81, P = 0.004). This is in line with the result of an earlier meta-analysis on isolated MV surgery [23] . In the Hamamoto study [15] the MV repair group had a higher, albeit statistically insignificant, rate of thromboembolism (RR: 1.60, P = 0.48). This was despite a lower prevalence of atrial fibrillation (AF) and higher use of bioprosthetic valves in the aortic position in the repair group compared with replacement. The reason for this finding was not clear. Similarly, TE risk was unexpectedly lower with MV repair when we analysed the three studies with exclusively RHD patients (RR: 0.48, 95% CI: 0.30-0.78 P = 0.003) [16] [17] [18] . However, this observation was largely driven by the study by Talwar et al. [17] (RR: 0.39, P = 0.001), which had unusually high rates of valve thrombosis in the replacement group. Patient-related factors like lack of adequate follow-up visits and poor compliance with anticoagulation could have been major contributing factors. Finally, bleeding is an inherent complication of anticoagulation therapy. The risk is potentially higher with prosthetic valves in the mitral than aortic position because of requirement for a higher target International Normalized Ratio (INR) [25] . Similarly, in patients with prosthetic valves in both the mitral and aortic positions, the need for more intense anticoagulation can be associated with a higher bleeding risk. Despite these facts, the current meta-analysis did not show any significant difference in the major bleeding rates between the two study groups (RR: 0.88, 95% CI: 0.49-1.57, P = 0.659) for reasons not known. This finding was replicated in the analysis of studies with exclusively RHD patients [16] [17] [18] (RR: 0.72, P = 0.35).
LIMITATIONS
As with any meta-analysis, our study is limited by the flaws inherent in each of the included studies, particularly from the bias incurred due to the non-randomized observational design. Individual studies in this meta-analysis did differ from each other with respect to their inclusion criteria, especially inclusion of patients undergoing simultaneous CABG. Prevalence of other baseline parameters like New York Heart Association functional class, LV dysfunction and coexisting coronary artery disease also differed between the two treatment groups and across individual studies. The surgical modality in a given patient was chosen based on the operating surgeon's assessment and hence could have introduced a selection bias. Furthermore, the presence of predominant mitral stenosis, severely damaged and calcified valve, and pre-existing AF were the main reasons for not resorting to a primary valve repair technique in some of the studies, which could have resulted in more favourable outcomes in the MV repair group. There was also great disparity among the studies and within individual studies regarding the types of repair techniques and the choice of prosthetic valves. Inconsistency among studies pertaining to anticoagulation management (INR range, maintenance and compliance) could have influenced our findings on TE and bleeding complications. Finally, incomplete and variable follow-up periods among individual studies could have resulted in censored data which can potentially influence some of the differences in the outcomes between the treatment groups.
CONCLUSION
In unselected patients undergoing concomitant mitral and AV surgery, MV repair is associated with improved early as well as late mortality and similar MV reoperation rates. However, in RHD patients, the survival advantage of the MV repair is abolished and there is a significantly higher need for MV reoperation. Hence, based on our analysis, MV replacement is preferable to repair in RHD patients who undergo dual valve surgery pending more data from randomized controlled trials.
